Literature DB >> 21572775

Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer.

Enock Anassi, Uche Anadu Ndefo.   

Abstract

Entities:  

Year:  2011        PMID： 21572775      PMCID： PMC3086121     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  16 in total

1.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

Authors:  E J Small; P Fratesi; D M Reese; G Strang; R Laus; M V Peshwa; F H Valone
Journal:  J Clin Oncol       Date:  2000-12-01       Impact factor: 44.544

2.  The role of immunotherapy in prostate cancer: an overview of current approaches in development.

Authors:  Michael Risk; John M Corman
Journal:  Rev Urol       Date:  2009

3.  Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853.

Authors:  D W Newling; L Denis; K Vermeylen
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

4.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

5.  Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Authors:  Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

Review 6.  Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.

Authors:  Punam H Patel; Denise R Kockler
Journal:  Ann Pharmacother       Date:  2007-12-19       Impact factor: 3.154

7.  Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Authors:  Patrick A Burch; Gary A Croghan; Dennis A Gastineau; Lori A Jones; Judith S Kaur; Jelle W Kylstra; Ronald L Richardson; Frank H Valone; Stanimir Vuk-Pavlović
Journal:  Prostate       Date:  2004-08-01       Impact factor: 4.104

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

10.  Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015.

Authors:  Robert A Bok
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423
View more
  50 in total

Review 1.  Ex Vivo Tumor-on-a-Chip Platforms to Study Intercellular Interactions within the Tumor Microenvironment.

Authors:  Vardhman Kumar; Shyni Varghese
Journal:  Adv Healthc Mater       Date:  2018-12-05       Impact factor: 9.933

Review 2.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

3.  Investigation of the potential anticancer effects of napelline and talatisamine dirterpenes on experimental brain tumor models.

Authors:  Merve Demirbağ Karaali; Elanur Aydın Karataş
Journal:  Cytotechnology       Date:  2020-06-11       Impact factor: 2.058

Review 4.  Surface engineering for lymphocyte programming.

Authors:  Elana Ben-Akiva; Randall A Meyer; David R Wilson; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2017-05-10       Impact factor: 15.470

Review 5.  A pharmacologic perspective on newly emerging T-cell manipulation technologies.

Authors:  Dominic Smethurst
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

6.  The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.

Authors:  Emad I Wafa; Sean M Geary; Jonathan T Goodman; Balaji Narasimhan; Aliasger K Salem
Journal:  Acta Biomater       Date:  2017-01-04       Impact factor: 8.947

7.  Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.

Authors:  Joanne O'Dwyer; Roisin E O'Cearbhaill; Robert Wylie; Saoirse O'Mahony; Michael O'Dwyer; Garry P Duffy; Eimear B Dolan
Journal:  Adv Ther (Weinh)       Date:  2020-08-16

Review 8.  Complex interplay between tumor microenvironment and cancer therapy.

Authors:  Minhong Shen; Yibin Kang
Journal:  Front Med       Date:  2018-08-10       Impact factor: 4.592

9.  Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.

Authors:  H Saito; K Kitagawa; T Yoneda; Y Fukui; M Fujsawa; D Bautista; T Shirakawa
Journal:  Cancer Gene Ther       Date:  2017-06-16       Impact factor: 5.987

Review 10.  Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?

Authors:  Rakesh R Ramjiawan; Arjan W Griffioen; Dan G Duda
Journal:  Angiogenesis       Date:  2017-03-30       Impact factor: 9.596
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.